United States newsroom

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 10, 2009-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...

Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy MELVILLE, N.Y.--(BUSINESS WIRE)-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S....

MELVILLE, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today's announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...

First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE,...

Arginine vasopressin (AVP) receptor antagonist now approved in single-use premixed formulation DEERFIELD, Illinois, October 22, 2008 — Astellas Pharma US, Inc. today announced that the U.S. Food...

DEERFIELD, IL, October 14, 2008 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched...

SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y.-- Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin®

Greater Chicago-area science teachers gain resources to inspire young scientists in the classroom DEERFIELD, IL, October 1, 2008 – Astellas Pharma US, Inc. (“Astellas”) is pleased to...

Vancouver, Canada and Deerfield, Illinois, USA, August 11, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease Deerfield, Ill., June 24, 2008 – Astellas Pharma US, Inc. today announced the commercial availability...